Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pemetrexed + sintilimab
- Development stage
- Discontinued
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Pemetrexed + sintilimab is a combination therapy consisting of pemetrexed, an antifolate antineoplastic agent, and sintilimab, an anti-programmed death 1 (PD-1) monoclonal antibody. Pemetrexed disrupts folate-dependent metabolic processes by inhibiting thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), which are essential for cell replication. Sintilimab blocks the interaction between PD-1 and its ligand, restoring T cell activity and enhancing immune response against tumor cells. This combination has been studied primarily for the treatment of nonsquamous non-small cell lung cancer (NSCLC).
02
Targets
DHFR (Dihydrofolate reductase)GART (GAR transformylase)TS (Thymidylate synthase)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pemetrexed + sintilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pemetrexed + sintilimab.